Lpl Financial LLC Cel Sci Corp Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Cel Sci Corp stock. As of the latest transaction made, Lpl Financial LLC holds 43,403 shares of CVM stock, worth $26,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,403

Previous 22,809 90.29%

Holding current value

$26,041

Previous $26,000 76.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$1.05 - $1.5 $21,623 - $30,891	20,594 Added 90.29%	43,403 $46,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $1,389 - $3,987	1,299 Added 6.04%	22,809 $62,000
Q3 2023 Nov 13, 2023	SELL	$1.17 - $2.86 $1 - $2	-1 Reduced -0.0%	21,510 $26,000
Q2 2023 Jul 31, 2023	BUY	$2.11 - $2.83 $2 - $2	1 Added 0.0%	21,511 $51,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $6,025 - $10,198	-1,950 Reduced 8.31%	21,510 $66,000
Q2 2022 Aug 12, 2022	BUY	$2.58 - $4.99 $4,386 - $8,483	1,700 Added 7.81%	23,460 $106,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $3 - $7	1 Added 0.0%	21,760 $86,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $23,430 - $42,306	3,300 Added 17.88%	21,759 $154,000
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $11,971 - $19,571	1,567 Added 9.28%	18,459 $203,000
Q2 2021 Aug 13, 2021	BUY	$8.68 - $27.49 $12,586 - $39,860	1,450 Added 9.39%	16,892 $147,000
Q1 2021 May 14, 2021	SELL	$12.0 - $27.64 $456 - $1,050	-38 Reduced 0.25%	15,442 $235,000
Q4 2020 Feb 12, 2021	BUY	$11.05 - $16.62 $33 - $49	3 Added 0.02%	15,480 $180,000
Q3 2020 Nov 09, 2020	BUY	$11.69 - $14.54 $180,926 - $225,035	15,477 New	15,477 $197,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Cel Sci Corp Transaction History